Japanese drug major Takeda Pharmaceutical (TYO: 4502) will invest in UK-based GammaDelta Therapeutics to develop its novel drug development technology.
GammaDelta is one of a number of companies interested in exploiting T cells, a subtype of white blood cells that are key to the body’s natural immune system.
It believes further research into gamma delta T cells, a unique type that contribute to many types of immune responses, could yield effective treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze